means to simplify and codify the information with which they work. This is evidenced early in their training, as exempli~ed in the mnemonic used to recall the names and sequence of the cranial nerves: "On old Olympus towering top. . . . " It is seen in the handbooks carried by junior house of~cers, to have ready access to information for which there is not instantaneous recall. And it is seen at all levels in medicine and biomedical science as we try to grasp, organize and prioritize the increasingly voluminous information that is applicable to patient care. This same approach carries over to our considerations of drugs: not only antiarrhythmics, but others, as well. A notable example is the antibiotics. The number of antibiotics available exceeds that of the antiarrhythmics, and the types of infections treated exceed by far the types of arrhythmias we treat. The Goodman and Gilman text [1] deals with the classi~cation of antibiotics as follows: a ten page table is provided on the "current use of antimicrobial agents in the therapy of infections." [2] Here, the primary descriptor for therapy is the offending microorganism, the secondary descriptor is the disease process that results, and therapy is prioritized as~rst, second, etc. choice, based on both basic and clinical investigation into mechanism, ef~cacy and toxicity. The classes of drugs, too, are considered in separate tables: and so we can review the general family of b-lactam antibiotics (all sharing a b-lactam ring), the subfamilies of this class, including penicillins and cephalosporins, and the speci~c members of each family, few of which are identical in structure or activity. The classi~cation and the approach to understanding, then, are based on the mechanism of the disease process (the microorganism and the resulting lesion), comprehension of the structure and the mechanism of action of the drugs, and the ability to thoughtfully~t this information together in a cohesive whole.
Classi~cation of Antiarrhythmic Drugs
The goals of an antiarrhythmic drug classi~cation system were well-stated by Nattel [3], as follows: "All drug classi~cations are ultimately a re_ection of our understanding of their pharmacology, the degree to which that pharmacology explains clinically important actions, and the extent to which drugs fall into groups with homogeneous pharmacological properties. In order to be usable, a classi~cation must be simple. If reality is a little more complicated than depicted by a given system, the system can be used with a recognition of the few exceptions. When the reality is much more complex than depicted by a classi~cation, use of the classi~cation requires so much additional knowledge that its value is limited. In the latter circumstances, application of the classi~cation without attention to these limitations can result in errors and inef~ciencies in drug development, understanding and use."
Although several classi~cation systems have been suggested, one of the oldest and certainly the most widely used is that of Vaughan Williams [4, 5] . As proposed in 1970 [4] , the classi~cation was rapidly adopted because of its utility as a teaching tool (it is physiologically based and readily learned). It has been used as well as a basis for new drug development and for designing approaches to clinical therapy. In its initial incarnation and early modi~cation, most notably by Singh and Vaughan Williams [6] and by Harrison et al. [7] (see Table 1 ), the system proposed four classes of drugs. All those in Class I shared a direct membrane action, blocking the fast inward Na current that contributes to the phase 0 upstroke of the normal atrial and ventricular myocardial and specialized conducting~ber action potentials. Class I was divided into three subclasses based primarily on the actions of the drugs on conduction, with phase 0 upstroke velocity and effect on repolarization and refractoriness being secondary descriptors. Class II encompassed all sympatholytic drugs, but rapidly evolved to a point where it included largely the b-adrenergic blockers. Class III was drugs that prolong repolarization, regardless of mechanism. Class IV was drugs that block Ca channels.
Whereas this system initially designated drugs as belonging to a particular class (e.g., quinidine as a Class I drug, amiodarone or d,l-sotalol as Class III) Vaughan Williams and others learned that the complexity of drug actions was far greater. As a result the attempt was made to consider the classes as representing "effects" that various drugs might exert. In this way, amio-darone is not a Class III drug, but a drug having not only Class III effects, but Class I, II and IV effects, as well. Nonetheless, for many years those in clinical medicine, basic science and drug development continued to apply the simplistic view engendered by the classi~cation system: as a result, a decade was spent trying to develop drugs that shared what was viewed as the major effect of the "prototypical" Class III compound, amiodarone-to prolong action potential duration. To date, while multiple drugs have been developed, they all share-and to an apparently greater degree than amiodarone-the propensity to induce torsades de pointes, and their therapeutic superiority (or even equality) to amiodarone has yet to be proven. More recently, we have begun to realize that the nonClass III actions of amiodarone (and conceivably other actions not even considered in the Vaughan Williams classi~cation, such as its thyroid effects) may also be of paramount importance to its ef~cacy.
There are other concerns about the Vaughan Williams classi~cation system, as summed up in the Sicilian Gambit publications [8, 9] . Among these concerns were that the "classi~cation (excluding class II) is primarily based on the effects of drugs on electrophysiological characteristics of isolated, normal cardiac tissues. However, in diseased tissues, where arrhythmias are likely to arise, channels and receptors are modi~ed, and the actions of drugs may be modi~ed as well. . . . The classi~cation does not incorporate the concept that antiarrhythmic drugs can be effective in various ways: slowing tachycardias and making them better tolerated, terminating established arrhythmias, or preventing arrhythmia initiation. . . . In simplifying matters, the classi~cation suggests we know more than we do. This can have serious consequences when physicians or regulatory agencies assume, without adequate information, that a drug in a given class will have the favorable and/or unfavorable effects characteristic of other drugs assigned to that same class" [8] .
Given the above concerns, a different view was taken concerning classi~cation by the members of the Sicilian Gambit [8, 9] . We supported a pathophysiologic approach to the treatment of cardiac arrhythmias; that is, an approach focussed on the mechanisms of arrhythmias rather than on the codi~cation of drug actions. We did this in part because, on reviewing the actions of antiarrhythmic drugs (see Fig. 1 ), we recognized that despite the commonalities of action of many drugs, there also are major disparities, such that each drug might best be understood in light of its own speci~c effects rather than as re_ecting some Class effect. As such, Figure 1 lists the actions of the drugs on a subset of ion channels and pumps (recognizing that this listing is, quite deliberately, incomplete) and provides data on some aspects of clinical action as well. While it is possible, and perhaps tempting, to codify the drug actions into a classi~cation based on this listing, it is more important to consider it as a focus for incorporating as much information as possible about individual drugs. Another point made by the Sicilian Gambit was that 
